Latest & greatest articles for adalimumab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adalimumab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adalimumab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adalimumab

81. Etanercept, adalimumab, infliximab and golimumab for the treatment of juvenile idiopathic arthritis

Etanercept, adalimumab, infliximab and golimumab for the treatment of juvenile idiopathic arthritis Etanercept, adalimumab, infliximab y golimumab para el tratamiento de artritis idiopática juvenil [Etanercept, adalimumab, infliximab and golimumab for the treatment of juvenile idiopathic arthritis] Etanercept, adalimumab, infliximab y golimumab para el tratamiento de artritis idiopática juvenil [Etanercept, adalimumab, infliximab and golimumab for the treatment of juvenile idiopathic arthritis (...) ] Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Alcaraz A, Lopez A, Rey-Ares L, Bardach A, Ciapponi A, Mengarelli C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Alcaraz A, Lopez A, Rey-Ares L, Bardach A, Ciapponi A, Mengarelli C. Etanercept, adalimumab, infliximab y

2014 Health Technology Assessment (HTA) Database.

82. Adalimumab

Adalimumab USE OF ADALIMUMAB IN PREGNANCY 0344 892 0909 USE OF ADALIMUMAB IN PREGNANCY (Date of issue: May 2015 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Adalimumab is a human monoclonal antibody administered in the treatment (...) of rheumatoid arthritis, enthesitis-related arthritis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, non-radiographic axial spondyloarthritis, psoriasis, Crohn’s disease, and ulcerative colitis. Its use in these conditions is reserved for patients where other systemic therapies are ineffective or unsuitable. There are very limited data specific to adalimumab use during pregnancy. Studies investigating the use of anti-TNFα therapies during pregnancy show no compelling evidence

2014 UK Teratology Information Service

83. Adalimumab (Humira) for severe chronic plaque psoriasis in children and adolescents ? second line

Adalimumab (Humira) for severe chronic plaque psoriasis in children and adolescents ? second line Adalimumab (Humira) for severe chronic plaque psoriasis in children and adolescents – second line Adalimumab (Humira) for severe chronic plaque psoriasis in children and adolescents – second line NIHR HSC Citation NIHR HSC. Adalimumab (Humira) for severe chronic plaque psoriasis in children and adolescents – second line. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review

2014 Health Technology Assessment (HTA) Database.

84. Adalimumab (Humira®)

Adalimumab (Humira®) Adalimumab (Humira®) Adalimumab (Humira®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Adalimumab (Humira®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat (...) Assessment Report Advice No. 2013. 2013 Authors' conclusions Adalimumab (Humira®) is recommended as an option for use within NHS Wales for the treatment of severe active Crohn's disease in paediatric patients (6 to 17 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy, a corticosteroid, and an immunomodulator, or who are intolerant to or have contraindications for such therapies. Final publication URL Indexing Status Subject indexing assigned

2013 Health Technology Assessment (HTA) Database.

85. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. (Abstract)

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Biological agents offer good control of rheumatoid arthritis, but the long-term benefits of achieving low disease activity with a biological agent plus methotrexate or methotrexate alone are unclear. The OPTIMA trial assessed different treatment adjustment strategies in patients with early (...) rheumatoid arthritis attaining (or not) stable low disease activity with adalimumab plus methotrexate or methotrexate monotherapy.This trial was done at 161 sites worldwide. Patients with early (<1 year duration) rheumatoid arthritis naive to methotrexate were randomly allocated (by interactive voice response system, in a 1:1 ratio, block size four) to adalimumab (40 mg every other week) plus methotrexate (initiated at 7·5 mg/week, increased by 2·5 mg every 1-2 weeks to a maximum weekly dose of 20 mg

2013 Lancet Controlled trial quality: predicted high

86. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial (Abstract)

Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial To evaluate the effect of adding a 10-week treatment of adalimumab to a standardised treatment with corticosteroids on the ability to taper more rapidly corticosteroid doses in patients with newly diagnosed giant cell arteritis (GCA).Patients included in this double-blind, multicentre controlled trial were randomly assigned to receive a 10-week subcutaneous treatment (...) of adalimumab 40 mg every other week or placebo in addition to a standard prednisone regimen (starting dose 0.7 mg/kg per day). The primary endpoint was the percentage of patients in remission on less than 0.1 mg/kg of prednisone at week 26. Analysis was performed by intention to treat (ITT).Among the 70 patients enrolled (adalimumab, n=34; placebo, n=36), 10 patients did not receive the scheduled treatment, seven in the adalimumab and three in the placebo group. By ITT, the number of patients achieving

2013 EvidenceUpdates Controlled trial quality: predicted high

87. Adalimumab (Humira®)

Adalimumab (Humira®) Adalimumab (Humira®) Adalimumab (Humira®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Adalimumab (Humira®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat (...) Assessment Report Advice No. 2113. 2013 Authors' conclusions Adalimumab (Humira®) is recommended as an option for use within NHS Wales, in combination with methotrexate, for the treatment of active polyarticular juvenile idiopathic arthritis, in children aged 2 to 4 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Adalimumab can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate

2013 Health Technology Assessment (HTA) Database.

88. Adalimumab (Humira®)

Adalimumab (Humira®) Adalimumab (Humira®) Adalimumab (Humira®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Adalimumab (Humira®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat (...) Assessment Report Advice No.1513. 2013 Authors' conclusions Adalimumab (Humira®) is recommended for use within NHS Wales for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of ankylosing spondylitis but with objective signs of inflammation by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have had an inadequate response to, or are intolerant to non steroidal anti-inflammatory drugs (NSAIDs). Final publication URL Indexing Status

2013 Health Technology Assessment (HTA) Database.

89. Adalimumab - Juvenile Idiopathic Arthritis

Adalimumab - Juvenile Idiopathic Arthritis Common Drug Review CDEC Meeting — June 19, 2013 Notice of CDEC Final Recommendation — July 18, 2013 Page 1 of 5 © 2013 CADTH CDEC FINAL RECOMMENDATION ADALIMUMAB (Humira — AbbVie Corporation) New Indication: Polyarticular Juvenile Idiopathic Arthritis Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that adalimumab be listed for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) if the following clinical criterion (...) and condition are met: Clinical Criterion: ? Inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs). Condition: ? Treatment should be initiated by a rheumatologist who is familiar with the use of DMARDs and/or biologic DMARDs in children. Reason for the Recommendation: One double-blind randomized controlled trial (RCT) (DE038; N = 133) demonstrated that adalimumab was superior to placebo for reducing the proportion of patients experiencing a disease flare, with or without

2013 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

90. Adalimumab (Humira) - in combination with methotrexate, for the treatment of active polyarticular juvenile idiopathic arthritis

Adalimumab (Humira) - in combination with methotrexate, for the treatment of active polyarticular juvenile idiopathic arthritis All Wales Medicines Strategy Group (AWMSG) - adalimumab (Humira) | | Appraisal information Search and reports adalimumab (Humira®) Reference No. 1977 Publication date: 15/08/2013 Appraisal information adalimumab (Humira®) 40 mg solution for injection Company: AbbVie Ltd BNF category: Musculoskeletal and joint diseases NMG meeting date: 19/06/2013 AWMSG meeting date: 17 (...) /07/2013 Submission Type: Limited Submission Status: Superseded Advice No: 2113 Ratification by Welsh Government: 14/08/2013 Current Progress Submission received NMG meeting AWMSG meeting Ratification by Welsh Government AWMSG advice AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA373) NICE GUIDANCE ISSUED DECEMBER 2015 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Adalimumab (Humira®) is recommended as an option

2013 All Wales Medicines Strategy Group

91. Adalimumab (Humira) - ankylosing spondylitis

Adalimumab (Humira) - ankylosing spondylitis All Wales Medicines Strategy Group (AWMSG) - adalimumab (Humira) | | Appraisal information Search and reports adalimumab (Humira®) Reference No. 1381 Publication date: 31/07/2013 Appraisal information adalimumab (Humira®) 40 mg solution for injection Company: AbbVie Ltd BNF category: Musculoskeletal and joint diseases NMG meeting date: 15/05/2013 AWMSG meeting date: 12/06/2013 Submission Type: Full Submission Status: Superseded Advice No: 1513 (...) Ratification by Welsh Government: 29/07/2013 Current Progress Submission received NMG meeting AWMSG meeting Ratification by Welsh Government AWMSG advice AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA383) NICE GUIDANCE ISSUED FEBRUARY 2016 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Adalimumab (Humira®) is recommended for use within NHS Wales for the treatment of adults with severe axial spondyloarthritis without

2013 All Wales Medicines Strategy Group

92. Humira (Adalimumab, Abbott Laboratories) for treatment of pediatric crohn's disease

Humira (Adalimumab, Abbott Laboratories) for treatment of pediatric crohn's disease Humira (Adalimumab; Abbott Laboratories) for treatment of pediatric crohn's disease Humira (Adalimumab; Abbott Laboratories) for treatment of pediatric crohn's disease Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Humira (Adalimumab; Abbott Laboratories) for treatment

2013 Health Technology Assessment (HTA) Database.

94. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, Full Text available with Trip Pro

Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, An investigator-initiated, double-blinded, placebo-controlled, treat-to-target protocol (Clinical Trials:NCT00660647) studied whether adalimumab added to methotrexate and intra-articular triamcinolone as first-line treatment in early (...) rheumatoid arthritis (ERA) increased the frequency of low disease activity (DAS28CRP<3.2) at 12 months.In 14 Danish hospital-based clinics, 180 disease-modifying anti-rheumatic drugs (DMARD)-naïve ERA patients (<6 months duration) received methotrexate 7.5 mg/week (increased to 20 mg/week within 2 months) plus adalimumab 40 mg every other week (adalimumab-group, n=89) or methotrexate+placebo-adalimumab (placebo-group, n=91). At all visits, triamcinolone was injected into swollen joints (max. four joints

2013 EvidenceUpdates Controlled trial quality: predicted high

95. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study Full Text available with Trip Pro

Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study To evaluate the efficacy and safety of adalimumab+methotrexate (MTX) in Japanese patients with early rheumatoid arthritis (RA) who had not previously received MTX or biologics.This randomised, double-blind, placebo-controlled, multicentre study evaluated adalimumab 40 mg every other week+MTX 6-8 mg every week versus MTX 6-8 (...) mg every week alone for 26 weeks in patients with RA (≤2-year duration). The primary endpoint was inhibition of radiographic progression (change (Δ) from baseline in modified total Sharp score (mTSS)) at week 26.A total of 171 patients received adalimumab+MTX (mean dose, 6.2±0.8 mg/week) and 163 patients received MTX alone (mean dose, 6.6±0.6 mg/week, p<0.001). The mean RA duration was 0.3 years and 315 (94.3%) had high disease activity (DAS28>5.1). Adalimumab+MTX significantly inhibited

2013 EvidenceUpdates Controlled trial quality: predicted high

96. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. (Abstract)

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Roughly a third of patients with rheumatoid arthritis treated with biological treatments receive them as monotherapy. Tocilizumab--an inhibitor of interleukin 6 receptor signalling--has been studied as monotherapy in several clinical trials. We assessed the efficacy and safety of tocilizumab monotherapy compared with adalimumab monotherapy (...) intravenously every 4 weeks plus placebo subcutaneously every 2 weeks or adalimumab 40 mg subcutaneously every 2 weeks plus placebo intravenously every 4 weeks for 24 weeks. Investigators, patients, and sponsor personnel were masked to assignment. The primary endpoint was change in disease activity score using 28 joints (DAS28) from baseline to week 24. This trial is registered with ClinicalTrials.gov, number NCT01119859.We screened 452 patients and enrolled 326 patients. The intention-to-treat population

2013 Lancet Controlled trial quality: predicted high

97. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis Full Text available with Trip Pro

Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis Soini EJ, Hallinen TA, Puolakka K, Vihervaara V, Kauppi MJ Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-utility of adalimumab, etanercept, and tocilizumab, as first biologic treatments for moderate-to-severe rheumatoid arthritis, after the failure of one or more traditional disease-modifying antirheumatic

2013 NHS Economic Evaluation Database.

98. Infliximab versus methotrexate, etanercept, adalimumab, and ustekinumab for plaque psoriasis: a review of the comparative clinical efficacy, safety and cost effectiveness

Infliximab versus methotrexate, etanercept, adalimumab, and ustekinumab for plaque psoriasis: a review of the comparative clinical efficacy, safety and cost effectiveness Infliximab versus methotrexate, etanercept, adalimumab, and ustekinumab for plaque psoriasis: a review of the comparative clinical efficacy, safety and cost effectiveness Infliximab versus methotrexate, etanercept, adalimumab, and ustekinumab for plaque psoriasis: a review of the comparative clinical efficacy, safety and cost (...) effectiveness CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Infliximab versus methotrexate, etanercept, adalimumab, and ustekinumab for plaque psoriasis: a review of the comparative clinical efficacy, safety and cost effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2012 Authors' conclusions Infliximab

2012 Health Technology Assessment (HTA) Database.

99. Adalimumab (Humira®)

Adalimumab (Humira®) Adalimumab (Humira®) Adalimumab (Humira®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Adalimumab (Humira®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat (...) Assessment Report Advice No. 0812. 2012 Authors' conclusions Adalimumab (Humira®) in combination with methotrexate is recommended as an option for use within NHS Wales for the treatment of active polyarticular juvenile idiopathic arthritis, in children and adolescents aged 4 to 17 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs. Adalimumab (Humira®) can be given as monotherapy in case of intolerance to methotrexate or when continued treatment

2012 Health Technology Assessment (HTA) Database.

100. Infliximab versus Methotrexate, Etanercept, Adalimumab, and Ustekinumab for Plaque Psoriasis: A Review of the Comparative Clinical Efficacy, Safety and Cost Effectiveness

Infliximab versus Methotrexate, Etanercept, Adalimumab, and Ustekinumab for Plaque Psoriasis: A Review of the Comparative Clinical Efficacy, Safety and Cost Effectiveness Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the best evidence on the topic (...) and used for non-commercial purposes, provided that attribution is given to CADTH. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Infliximab versus Methotrexate, Etanercept, Adalimumab, and Ustekinumab for Plaque Psoriasis: A Review of the Comparative Clinical Efficacy, Safety and Cost

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review